Kura Oncology (KURA) and Kyowa Kirin Co. announced that the first patient has been dosed under the KOMET-017 clinical trial protocol (NCT07007312), comprising two independent, global, randomized double-blind, placebo-controlled Phase 3 trials to evaluate ziftomenib, Kura Oncology’s investigational menin inhibitor, in combination with both intensive and non-intensive combination regimens in patients with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology’s ziftomenib meets primary endpoint in AML study
- Promising Developments in Kura Oncology’s FTI Programs Highlighted by Analyst Buy Rating
- Kura Oncology’s Strategic Positioning and Promising Developments Justify Buy Rating
- Kura Oncology reports inducement grants under Nasdaq listing rule
- Kura Oncology initiated with a Neutral at Guggenheim